CORONA Remedies Schedules Q1 FY27 Earnings Call for Aug 3, 2026
CORONA Remedies Limited will hold its Q1 FY27 earnings conference call on August 3, 2026, at 11:30 a.m. IST to discuss financial results for the quarter ended June 30, 2026. Management team members will be present.
This is a standard procedural announcement regarding an upcoming investor call and does not contain material financial information or strategic changes that would significantly impact the company's stock or operations.
The announcement is a routine intimation of a scheduled conference call for discussing financial results and does not contain any specific financial performance data or forward-looking statements that would indicate a positive or negative sentiment.
CORONA Remedies Limited has announced its Q1 FY27 earnings conference call, scheduled for Monday, August 03, 2026, at 11:30 a.m. IST. The call will focus on discussing the financial results for the first quarter and three months ended June 30, 2026.
The management team, including Managing Director & CEO Mr. Nirav Mehta, Joint Managing Director Mr. Ankur Mehta, and Chief Financial Officer Mr. Bhavin Bhagat, will represent the company during the call. The event is being organized by 360 ONE CM Research.
Details for participation include a Diamond Pass registration link and universal dial-in numbers for both domestic and international callers. Further information can be obtained by contacting Mr. Rohit Bhat or Mr. Maulik Varia from 360 ONE Capital Market Research.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.